Rev Osteoporos Metab Miner. 2011; 3 (4): 141-6
2 Departamento de Epidemiología y Medicina Preventiva – Facultad de Medicina de Granada – Granada
3 Departamento de Investigación – Puleva Biotech – Granada
Introduction: The results of the works published on the role of isoflavones in the prevention of postmenopausal osteoporosis are contradictory. The objective of our study is to evaluate the effects of nutritional intervention with a milk product enriched with soy isoflavones on bone metabolism in Spanish postmenopausal women.
Subjects and methods: A randomised controlled double blind trial was carried out in 99 postmenopausal women who were allocated to two groups: group S (n=48), with a consumption of a milk product enriched with soy isoflavones (50mg/day), and group C (n=51), with a consumption of a control milk product over 12 months. Hormone parameters and markers for bone metabolism were assessed at the baseline and at one year. Ultrasound of the calcaneum (QUS, Hologic Sahara®, North Carolina, US.) was used as the evaluation tool for bone mass.
Results: At 12 months, a decrease in blood levels of tartrate-resistant acid phosphatase and osteoprotegerin occurred (2.18 ± 0.8 vs 1.76 ± 0.54 U/l, p<0.001, and 5.21 ± 3.36 vs 3.89 ± 1.47 pmol/L, p=0.007, respectively), as well as an increase in 25-OH-vitamin D (24.48 ± 9.85 vs 28.18 ± 10.45 ng/ml, p<0.001 ) with no differences between the groups. There were no significant changes in hormone parameters and the rest of the bone markers. In terms of the QUS, in the total sample there was an increase in the sound velocity [SOS] (1517.86 ± 38.13 vs 1525.11 ± 35.6 m/s, p=0.036), QUI (76.37 ±19.87 vs 80.82 ± 18.26, p=0.012 ), estimated bone mineral density [Est. BMD] (0.408 ± 0.13 vs 0.435 ± 0.12 g/cm², p=0.013) and T-score (-1.55 ± 1.12 vs -1.31 ± 1.03, p=0.019). In group S, positive changes occurred in QUI (74.37 ± 18.87 vs 78.83 ± 13.68, p=0.032) and Est. BMD (0.397 ± 0.12 vs 0.423 ± 0.09 g/cm², p=0.04), whilst in group C there were no significant differences.
Conclusions: The daily consumption of these milk products increases levels of 25-OH-vitamin D and results in a decrease in markers for bone metabolism. A diet rich in soy isoflavones may be an option as a preventative measure against the effects of the menopause on bone.
The post- and peri-menopausal periods are a physiological state characterised by the cessation of ovarian hormonal secretion, leading to significant physiological and psychosocial changes in the lives of women1.
In the light of the adverse effects of hormone replacement therapy, there has been increased interest in alternatives to improve menopausal symptoms and their long-term complications. The phytoestrogens are non-steroidal compounds which are structurally and/or functionally related to the placental or ovarian estrogens, and which may have antagonistic, agonistic or partial effects on the estrogen receptor. The isoflavones are the most active phytoestrogens, the most notable being those found in soya.
Due to this similarity with estradiol, the action of the phytoestrogens is mediated by the estrogenic receptors (ER) α and β. Their tissue distribution is different, the action of their natural or synthetic ligands having specific effects in each tissue. The isoflavones have greater affinity for ERβ. This finding has been put forward to explain the low incidence of clinical effects associated with the menopause in countries with a high consumption of phytoestrogens. Also, lower stimulatory effects are obtained in the breast and endometrium compared with 17β-estradiol, which triggers the transcriptional pathway of ERα2.
Taking into account these data, foods enriched with soya isoflavones could be considered as “functional foods” – those which include a component which provides a specific beneficial physiological, in addition to a purely nutritional, effect, and which results in an improvement in the state of health and contribute to the risk of developing diseases3.
The aim of our study is to evaluate the effects of nutritional intervention with a milk product enriched with soya isoflavones on the bone metabolism of Spanish postmenopausal women.
Subjects and methods
This nutritional study was carried out with a randomised, controlled double blind design. The participants were recruited from the Endocrinology Clinic at the Centre for Specialisation in the University Hospital of San Cecilio, Granada. They all gave their signed informed consent to be included. The study was carried out with the approval of the Ethics Committee of the hospital, and was adjusted to meet the relevant directives for research in humans.
99 postmenopausal women between 45 and 65 years of age with physiological amenorrhea of at least one year’s development, were selected. The study excluded patients with: serious cardiorespiratory, renal, hepatic or gastrointestinal disease; any hormonal drug treatment or any treatment affecting bone mass or vitamin D metabolism, including calcium and vitamin D supplements. The participants were distributed by random sampling into two groups: Group S, with 48 women, who consumed the milk product enriched with isoflavones, and Group C, of 51 women, who consumed a control milk product. The daily amount of both products consumed was 500 ml over 12 months. In Group S, the daily quantity of isoflavones administered was 50 mg (Table 1).
At the start of the study epidemiological data was collected regarding age, time of development of the menopause, smoking habits and consumption of alcohol, and a basic physical examination was carried out to determine the body mass index (BMI) and the systolic (SPL) and diastolic (DPL) pressure levels.
Measurements were taken at the baseline and at 12 months for hormones, biochemistry and markers for remodelled bone. The hormonal data analysed were: follicle-stimulating hormone (FSH), leutinising hormone (LH) and 17β-estradiol. In addition, blood levels of calcium, phosphorus, parathormone, 25-OH-vitamin D and osteoprotegerin (OPG, ELISA BI-20402, BIO-MEDICA-GRUPPE. Wien, Austria) were measured. The markers for remodelled bone for formation measured were osteocalcin (OC, electrochemiluminescence immunoassay, analyser Elecsys, Roche Diagnostics, IN) and bone alkaline phosphatase (FAO, ELISA, Tandem-R Ostase TM, Hybritech Europe, Liege, Belgium). The markers for resorption included were tartrate-resistant acid phosphatase 5β (TRAP5β, colourimetry, Hitachi 704 Boehringer Manheim GmbH) and carboxy-terminal telopeptide of type I collagen (CTX, enzymatic immunoassay, analyser Elecsys CrossLaps, Roche Diagnostics SL, Barcelona, Spain).
At the start of the study and at 12 months bone mass was estimated using ultrasound of the calcaneum (QUS, Hologic® Sahara® Waltham, NC, USA). The parameters provided were: speed of sound (SOS), attenuation coefficient (BUA, broadband ultrasound attenuation), QUI [QUI = 0.41(SOS) + 0.41(BUA) – 571)], and estimated bone mineral density [Est. BMD = 0.002592 × (BUA+SOS) – 3.687 g/cm2]. The measurements were carried out in the dominant foot in the manufacturers’ standard conditions4,5.
The statistical programme used was SPSS version 15.0. The quantitative variables were expressed as averages and standard deviations (SD) and the dichotomous variables as a percentage. The normality of the variables was analysed using the Kolmogorov-Smirnov test. A value of p<0.05 was considered to be statistically significant. For the comparison of the qualitative variables the chi-squared test was used. In the quantitative variables the t-student average comparison test for independent samples (intergroup differences) and paired samples (intragroup differences) was used.
The average age was 55.8 years (SD=6.9) with an average menopausal development time of 3.9 years (SD=4.1). 76.8% did not consume alcohol and 79.8% did not smoke. The average BMI was 28.35 kg/m² (SD=4.67); the average SPL, was 126 mmHg (SD=18) and DPL, 79 mmHg (SD=11). Statistically significant differences were found in the two groups (Group C compared with Group S) in the period of development of the menopause: 5.8 years (SD=3.7) as opposed to 7.9 years (SD=4.2), p=0.008.
Development of markers for bone metabolism
Table 2 specifies the markers for bone metabolism in the population studied during the follow up period.
In the total sample there was an increase in blood concentration of 25-OH-vitamin D (p<0.001). In addition, the OPG (p=0.007) and the TRAP (p<0.001) diminished. Notable in Group C was the increase in the blood concentration of 25-OH-vitamin D (p=0.023). There was a decrease in OPG (p=0.05) and TRAP (p=0.001). In Group S there was also an increase in blood concentration of 25-OH-vitamin D (p=0.001) and a decrease in OPG (p=0.037) and TRAP (p<0.001). No statistically significant differences were found between the two groups in the rest of the measurements.
Development of bone mass estimated by ultrasound of the calcaneum
The parameters measured by QUS are shown In Table 3 and Figure 1.
In the total sample there was a significant increase in SOS (p=0.036), QUI (p=0.012), and estimated BMD (p=0.013) and T-score (p=0.019) between the start and after 12 months of the study. In Group C these changes were not significant, while in Group S there were favourable changes in QUI (p=0.032) and estimated BMD (p=0.04). There were no statistically significant differences found between the two groups.
One of the central problems in relation to functional foods is to establish a scientific basis on which to support the beneficial properties which are attributed to their components. The epidemiological evidence suggests that the consumption of soya products is beneficial in relation to problems associated with the menopause. In this context we proposed to evaluate the effects of nutritional intervention with a milk product enriched with soya isoflavones on the bone metabolism in a group of Spanish postmenopausal women. In our study, the consumption of soya isoflavones resulted in favourable changes in bone mass.
Postmenopausal osteoporosis translates clinically into an increase in the risk of fracture and is a public health problem6. The observation that women from southeast Asia show a lower incidence of osteoporosis led to the hypotheses that the phytoestrogens from soya could be an alternative for the prevention of loss of bone mass associated with the menopause.
The role of the estrogens in vitro is to inhibit the development of the osteoclasts, favouring their apoptosis by stimulating the production of growth transformation factor beta (TGF-β) by the osteoblasts, in addition to inhibiting the production of interleukin 6 (IL-6), the principal stimulant for resorption. They also prevent osteoblast apoptosis. Deficiency estrogen also increases the apoptosis of the osteocytes, which alters the mechano-sensory function of the canalicular system for repairing microdamage, contributing to bone fragility7. The action mechanism by which the isoflavones protect against bone loss is not completely known, it being suggested that they modulate the receptor activator osteoprotegerin/ligand system for nuclear factor κB (OPG/RANKL). With estrogen deficiency the production of OPG reduces and there is a strong response by the osteoclast precursors to RANKL8. The isoflavones, and specifically the genisteins, stimulate the activity of the osteoprotegerin. Moderate activity is sufficient to stimulate bone formation9,10.
The clinical studies carried out are highly variable in terms of their design, taking into account the duration of the supplementation, the dose prescribed and taken, the source of soya used, or the epidemiological characteristics of the population. A meta-analysis which reviewed ten clinical trials concluded that nutritional intervention with isoflavones could attenuate bone loss in the spines of postmenopausal women11, coinciding with the findings of Marini et al. who confirmed how treatment over two years with genistein had positive effects in the BMD of postmenopausal women with osteopenia12. A study of the effect on ultrasound of the calcaneum obtained similar results13. However, in spite of these favourable results there are also works which do not give evidence of change14. A recent intervention study in premenopausal women which evaluated the status of various ions, markers for bone metabolism and thyroid function found no differences in these parameters after the incorporation in the diet over ten weeks of soya isoflavones15.
It can be said that, although there is some experimental evidence which suggests a relationship between the consumption of isoflavones and an improvement in bone condition, these are not considered to be conclusive16.
In relation to our results, there was a decrease in blood concentrations of TRAP and OPG and an increase in levels of vitamin D without differences between groups, which may be explained by the calcium and 25-OH-vitamin D contained in the milk preparations used. With respect to the evaluation of bone mass through ultrasound in the calcaneum, a global increase was observed in all the parameters after a year of follow up, although the changes in QUI and estimated BMD in the group which consumed soya isoflavones were significant.
Our work suffers from some methodological limitations which do not make it possible to be certain whether the differences encountered were solely due to the supplementation with soya isoflavones. One way, hypothesis contrast models used are valid as a statistical method for comparison between groups. In conclusion, the daily consumption of these milk products increases levels of 25-OH-vitamin D and results in a decrease in markers for bone remodelling. A diet rich in soya isoflavones may be an option as a preventative measure against the effects of the menopause on the bone.
Conflict of interest: JFC is a member of the Research Department of Puleva Biotech, Granada, Spain.
1. Martin KA, Manson J. Approach to the patients with menopausal symptoms. J Clin Endocrinol Metab 2008;93:4567-75.
2. Lorraine A, Fitzpatrick MD. Phytoestrogens-mechanism of action and effect on bone markers and bone mineral density. Endocrinol Metab Clin N Am 2003;32:233-52.
3. De Luis DA, Pérez Castrillón JL, Aller R, Culebras J. Influencia del consumo de soja sobre la masa ósea. An Med Interna 2007;24:361-4.
4. López-Rodríguez F, Mezquita-Raya P, de Dios Luna J, Escobar-Jiménez F, Muñoz-Torres M. Performance of quantitative ultrasound in the discrimination of prevalent osteoporotic fractures in a bone metabolic unit. Bone 2003;32:571-8.
5. Sosa Henríquez M, Saavedra SP, Alegre López J, Gómez Alonso C, González Macías J, Guañabens Gay N, et al. Prevalencia de osteoporosis en la población española por ultrasonografía de calcáneo en función del criterio diagnóstico utilizado. Datos del estudio GIUMO. Rev Clin Esp 2003;203:329-33.
6. Muñoz-Torres M, Alonso G et al. Prevención y tratamiento de la osteoporosis. Endocrinol Nutr 2003;50:1-7.
7. Dempter DW. The pathophysiology of bone loss. Clin Geriatr Med 2003;19:259-74.
8. Riggs BL, Khosla S, Melton LJ 3rd. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 2002;23:279-302.
9. Morris C, Thorpe J, Ambrosio L, Santin M. The soybean isoflavone genistein induces differentiation of MG63 human osteosarcoma osteoblasts. J Nutr 2006;36:1166-70.
10. Crisafulli A, Altavilla D, Squadrito G. Effects of the phytoestrogen genistein on the circulating soluble receptor activator of nuclear factor kappa_ ligand oestoprotegerin sustem in early postmenopausal women. J Clin Endocrinol Metab 2004;89:188-92.
11. Ma DF, Qin LQ, Wang PY, Katoh R. Soy isoflavones intake increases bone mineral density of menopausal women: Meta-analysis of randomized controlled trials. Clin Nutr 2008;27:57-64.
12. Marini H, Manutoli L, Polito F, Bitto A, Altavilla D, Atteritano M, et al. Effects of the phytoestrogen genestein of bone metabolism in osteopenic postmenopausal women. Ann Inter Med 2007;146:839-47.
13. Atteritano M, Mazzaferro S, Frisina A, Cannata ML, Bitto A, D’Anna R, et al. Genestein effects on quantitative ultrasound parameters and bone mineral density in osteopenic postmenopausal women. Osteoporos Int 2009;20:1947-54.
14. Horiuchi T, Onouchi T, Takahashi M, Ito H, Orimo H. Effect of soy protein on bone metabolism in postmenopausal Japanese women. Osteoporos Int 2000;11:721–4.
15. Zhou Y, Alekel DL, Dixon PM, Messina M, Reddy MB. The effect of soy food intake on mineral status in premenopausal women. J Womens Health 2011 Apr 12. [Epub ahead of print].
16. Cassidy A, Albertazzi P, Lise Nielsen I, Hall W, Williamson G, Tetens I, et al. Critical review of health effects of soybean phytoestrogens in post-menopausal women. Proc Nutr Soc 2006;65:76-92.